Biosimilars: Benchmarking the key players

Questions: Discounts, Updates etc.

Price: $7,600.00

Publication Date: 2006-12-20

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

With increasing regulatory clarity and the expiries of key patents covering innovator biologics, the development of biosimilars for a range of recombinant protein classes is becoming increasingly attractive. Although many companies are targeting the market, 12 companies dominate. These include established generics companies, leading biosimilars developers, plus emerging biosimilar developers.


Scope

  • Overview of the biosimilars competitive landscape, examining how the key players dominate the environment
  • Update of in-depth profiles of the top-12 biosimilar developers
  • Identification of licensing and collaboration trends shaping the biosimilars environment
  • Analysis of biosimilar development trends in terms of target protein class, drug delivery and reformulation technology, and geographical launch market


    • Report Highlights
    Well-established generics companies such as Sandoz and Teva have led the drive into the biosimilars market, by launching across a range of emerging and Western markets in a small number of well-characterized and relatively simple recombinant protein classes with significant market potential.

    Although established generics companies have so far dominated the biosimilars landscape, emerging biosimilar developers have the greatest number of disclosed pipeline biosimilar programs, which are set to broaden the range of biosimilars being developed in terms of protein class, drug delivery and formulation.

    There has been significant licensing and M&A deal activity among the top-12 biosimilar companies, enabling them to build a stronger product portfolio and gain greater access to capabilities that are key to competing in this market, such as drug delivery (primarily advanced injection technology) and drug formulation (mainly pegylation) technologies.


    Reasons to Purchase

  • Evaluate the competitive landscape of the top-12 biosimilar developers
  • Identify the trends shaping biosimilar product development among the top-12 biosimilar developers
  • Understand the drivers for licensing and M&A deals being conducted by the top-12 biosimilar developers

    • Table of Contents

    Other users found this report page using the following search terms: Biosimilars generics biosimilars pegylation ratiopharm players hospira issues regulatory biosimilar products biogenerix

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.